ASJC Scopus subject areas
- Internal Medicine
Access to Document
Other files and links
Changes Associated with the Entry of a Biosimilar in the Insulin Glargine Market. / Levy, Joseph; Chowdhury, Zahra M.; Socal, Mariana P. et al.In: JAMA internal medicine, Vol. 181, No. 10, 10.2021, p. 1405-1407.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Changes Associated with the Entry of a Biosimilar in the Insulin Glargine Market
AU - Levy, Joseph
AU - Chowdhury, Zahra M.
AU - Socal, Mariana P.
AU - Trujillo, Antonio J.
N1 - Funding Information: Funding/Support: This work was supported by a grant from Arnold Ventures LLC. Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 1. Atteberry P, Bach PB, Ohn JA, Trusheim MR. Biologics are natural monopolies (part 1): why biosimilars do not create effective competition. Health Affairs Blog. Accessed December 24, 2020. https://www.healthaffairs.org/do/10.1377/ hblog20190405.396631/full/ 2. Hernandez I, Good CB, Shrank WH, Gellad WF. Trends in Medicaid prices, market share, and spending on long-acting insulins, 2006-2018. JAMA. 2019; 321(16):1627-1629. doi:10.1001/jama.2019.2990 3. San-Juan-Rodriguez A, Gellad WF, Good CB, Hernandez I. Trends in list prices, net prices, and discounts for originator biologics facing biosimilar competition. JAMA Netw Open. 2019;2(12):e1917379. doi:10.1001/ jamanetworkopen.2019.17379 4. Boehringer Ingelheim. FDA approves Basaglar (insulin glargine injection), a long-acting insulin treatment. News release. Accessed April 18, 2021. https:// www.boehringer-ingelheim.us/press-release/fda-approves-basaglarr-insulin-glargine-injection-long-acting-insulin-treatment 5. Kakani P, Chernew M, Chandra A. Rebates in the pharmaceutical industry: evidence from medicines sold in retail pharmacies in the US. National Bureau of Economic Research working paper 26846. March 2020. Accessed May 24, 2021. https://www.nber.org/papers/w26846 6. Fowler AC. Hurry up or wait? strategic delay in the introduction of pharmaceutical line extensions. Working paper. December 23, 2019. Accessed May 24, 2021. https://scholar.harvard.edu/files/afowler/files/Fowler_JMP.pdf
PY - 2021/10
Y1 - 2021/10
UR - http://www.scopus.com/inward/record.url?scp=85108895096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108895096&partnerID=8YFLogxK
U2 - 10.1001/jamainternmed.2021.2769
DO - 10.1001/jamainternmed.2021.2769
M3 - Letter
C2 - 34180955
AN - SCOPUS:85108895096
VL - 181
SP - 1405
EP - 1407
JO - Archives of internal medicine (Chicago, Ill. : 1908)
JF - Archives of internal medicine (Chicago, Ill. : 1908)
SN - 2168-6106
IS - 10